Biotech Values

[DewDiligence]

Re: Safety of long-term treatment:

[Addendum to #6634]

>>The systemic issues in those other drugs showed up fairly quickly. Why didn't we see those problems in the [Squalamine] cancer trials with very large dosage levels? <<

Actually (if you believe Merck), the cardiotoxicity of Vioxx does not become significant until a patient has been on continuous therapy for at least 18 months.

No clinical trials have tested Squalamine treatment for anywhere near that long. From a safety standpoint, long-term following of patients is not nearly as illuminating as long-term treatment.